RXK3 Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SELLAS Life Sciences Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.12 |
| 52 Week High | US$1.64 |
| 52 Week Low | US$0.45 |
| Beta | 2.4 |
| 11 Month Change | 11.58% |
| 3 Month Change | -5.41% |
| 1 Year Change | 23.81% |
| 33 Year Change | -81.15% |
| 5 Year Change | -73.76% |
| Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| RXK3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -0.2% | 0.8% |
| 1Y | 23.8% | -16.9% | 9.1% |
Return vs Industry: RXK3 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: RXK3 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| RXK3 volatility | |
|---|---|
| RXK3 Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RXK3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RXK3's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Angelos Stergiou | www.sellaslifesciences.com |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials.
SELLAS Life Sciences Group, Inc. Fundamentals Summary
| RXK3 fundamental statistics | |
|---|---|
| Market cap | €78.56m |
| Earnings (TTM) | -€30.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs RXK3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RXK3 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$32.28m |
| Earnings | -US$32.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RXK3 perform over the long term?
See historical performance and comparison